Item 2.02 Results of Operations and Financial Condition. On May 3, 2022, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 3, 2022, Biogen Inc. (the "Company") announced that it had begun a search for a new Chief Executive Officer ("CEO"). The Company has agreed with its current CEO, Michel Vounatsos, that he will continue to serve as CEO during the interim period, receiving the same compensation and benefits, as well as pro-rated vesting of equity awards, for the period he is CEO. Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



The exhibits listed below are furnished as part of this Current Report on Form
8-K.
Exhibit No.              Description
                           Letter r    egarding employment arrangement of Michel Vounatsos dated
10.1                     May 2, 2022
99.1                       Biogen's press release dated May 3, 2022
                         Cover Page Interactive Data File (embedded within the Inline XBRL
104                      document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses